CIM
KERX

Cambria Investment Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Cambria Investment Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,240
Closed -$4K – 304
2015
Q3 		$4K Hold
1,240
– – ﹤0.01% 312
2015
Q2 		$12K Buy
1,240
+1,018
+459% +$10.9K ﹤0.01% 238
2015
Q1 		$3 Hold
222
– – ﹤0.01% 224
2014
Q4 		$3K Buy
+222
New +$3.44K ﹤0.01% 230

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cambria Investment Management's KERX Position: Q4 2015 in Review

Cambria Investment Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2015, closing a stake of 1,240 shares — an estimated $4K sold.

Cambria Investment Management first reported a position in KERX in Q4 2014 and held it in 4 quarters. The position peaked at $12K in Q2 2015. 128 funds tracked by Wall St. Rank hold KERX as of Q4 2015.

  • Cambria Investment Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Cambria Investment Management sold 1,240 Keryx Biopharmaceuticals Inc shares in Q4 2015, an estimated $4K.
  • Cambria Investment Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 4 quarters.
  • Cambria Investment Management's Keryx Biopharmaceuticals Inc position peaked at $12K in Q2 2015.
  • 128 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2015.

Based on Cambria Investment Management's 13F filing for Q4 2015, filed 11 Feb 2016.